沙库巴曲缬沙坦治疗慢性心力衰竭患者的效果被引量：10

导出

摘要目的探讨沙库巴曲缬沙坦治疗慢性心力衰竭患者的效果。方法回顾性分析2011年6月至2018年7月于南阳市第二人民医院住院的慢性心力衰竭患者127例,根据纳入排除标准最后共98例慢性心力衰竭患者入组,按照治疗方案的不同将患者分为A组和B组,每组49例。两组接受标准抗心衰治疗,包括给予盐酸贝那普利、β受体阻滞剂和利尿剂,在此基础上A组患者服用沙库巴曲缬沙坦治疗,对比分析治疗后疗效及心功能情况。结果治疗后A组患者总有效率(87.8%)高于B组(77.6%),差异有统计学意义(P<0.05)。治疗后A组6分钟步行距离长于B组,差异有统计学意义(P<0.05)。治疗后A组患者LVEF高于B组患者,LVEDD、NT-proBNP低于B组患者,差异有统计学意义(均P<0.05)。结论沙库巴曲缬沙坦可以改善心衰患者心功能。

作者郭广艳张洪

机构地区南阳市宛城区疾病预防控制中心南阳市第二人民医院心衰监护室

出处《河南医学研究》 CAS 2020年第12期2186-2188,共3页 Henan Medical Research

关键词慢性心力衰竭沙库巴曲缬沙坦比索洛尔

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献4

1黄峻.慢性心力衰竭临床研究的新趋势[J].中华心血管病杂志,2007,35(7):593-594. 被引量：44
2邱爽,杨波,平海芹,王慧,周三凤.血管紧张素受体脑啡肽酶抑制剂在心力衰竭中的研究进展[J].中国循环杂志,2015,30(11):1131-1133. 被引量：27
3黄进宇.慢性心力衰竭的药物治疗进展[J].心电与循环,2018,37(2):83-85. 被引量：12
4栾曾惠,张亚同,赵紫楠,胡欣.沙库巴曲缬沙坦快速技术评估[J].临床药物治疗杂志,2017,15(11):50-53. 被引量：21

二级参考文献33

1姜红,葛均波.心力衰竭流行病学特点[J].中国医学前沿杂志（电子版）,2010,2(1):1-5. 被引量：92
2McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in prospective cmnparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail, 2014, 16: 817-825.
3Packer M, McMurray JJ, Desai AS , et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131: 54-61.
4McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J, 2015, 36: 434-439.
5von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfimction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy. Circ Heart Fail, 2015, 8: 71-78.
6Bavishi C, Messerli FH, Kadosh B, et al. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J, 2015, 36: 1967-1973.
7McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 2014, 371: 993 - 1004.
8Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin- angiotensin system inhibition for the treatment of heart failure. JACC Heart Failure, 2014, 2:663 - 670.
9McMurray J J, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impaet on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). EurJ Heart Fail, 2013, 15: 1062-1073.
10Fitippatos G, Farmakis D, Parissis J, et al. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Med, 2015, 13: 35.